Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(50%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_3
1
25%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(2)
Other(2)

Detailed Status

unknown2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

unknown250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
terminatednot_applicable

Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study

NCT00968799
terminatedphase_2

Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study

NCT03150628
unknownphase_3

Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma

NCT02328716
unknownphase_2

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

NCT01786018

Clinical Trials (4)

Showing 4 of 4 trials
NCT00968799Not Applicable

Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study

Terminated
NCT03150628Phase 2

Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study

Terminated
NCT02328716Phase 3

Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma

Unknown
NCT01786018Phase 2

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

Unknown

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4